Drug intelligence / Profile preview

2-(chloromethyl)-4-methylquinazoline

Development stage: Preclinical
Lead developer: Krufren Pharma
Modality: Small Molecules

Overview

2-(chloromethyl)-4-methylquinazoline is a small molecule drug candidate currently in the pipeline of Krufren Pharma. It is being developed for the treatment of rare diseases. As a quinazoline derivative, this compound represents a scaffold often utilized in medicinal chemistry for its diverse biological activities, including potential roles as kinase inhibitors or modulators of protein-protein interactions. The asset is currently in the early stages of development, with specific molecular targets and clinical indications within the rare disease space yet to be fully detailed by the developer.

Beyond the preview

Go deeper on 2-(chloromethyl)-4-methylquinazoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2-(chloromethyl)-4-methylquinazoline.

Explore the full profile